Multiple Myeloma Group Honours Project #5: Targeting Ras/Raf/MAPK and PI3K/Akt pathways as potential therapeutic targets in multiple myeloma CONTACT EMAIL: [email protected] Multiple myeloma (MM), the second most prevalent blood cancer after non-Hodgkin’s lymphoma, is a clonal malignancy of plasma cells. MM is characterized by the presence of a monoclonal protein in serum and/or urine, widespread osteolysis, renal failure and anaemia. MM remains incurable despite significant advances in treatment over the past decade with successive relapses manifesting increasing drug resistance, invariable culminating in uncontrollable and fatal disease. New treatments are constantly sought to overcome this disease. Two well characterised pathways, the Ras/Raf/MAPK and PI3K/Akt pathways are constitutively activated through multiple mechanisms and has major roles in MM development and progression. A wide spectrum of Ras/Raf/MAPK and PI3K/Akt inhibitors have been discovered and entered clinical trials but the effects of their individual use has been disappointing. We hypothesized that dual targeting of these two pathways would be an effective strategy against MM. Therefore this project is to target both pathways using novel chemotherapeutics and assess its therapeutic effects against MM.
Posted on: Wed, 24 Jul 2013 23:16:55 +0000
Trending Topics
Recently Viewed Topics
© 2015